: iStockAnalyst.com Symbols Feed

Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities

Tue, 29 Sep 2009 19:31:31 GMT

Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).[More...]

BioMed News Bytes: NicOx, Allos, YM BioSciences

Fri, 25 Sep 2009 19:34:40 GMT

On 5/19/09, NicOx (EPA: COX.PA) announced that quality of life and utility results from its first Phase 3 clinical trial for naproxcinod were presented at the International Society For Pharmacoeconomics and Outcomes Research Annual International Meeting in Orlando, FL. Naproxcinod is a novel type of anti-inflammatory agent, which completed a Phase 3 clinical program last year in patients with osteoarthritis.[More...]

Small-Cap Stocks Battling Brain Cancer

Tue, 08 Sep 2009 00:02:23 GMT

Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH statistics, with Schering-Plough's (NYSE:SGP) Temodar (temozolomide or TMZ is classified as a DNA-methylating chemotherapy drug) given to nearly every patient with a diagnosis of GBM (the most common and aggressive form of brain cancer).[More...]

9 New Stock Picks: Tim Alerts

Mon, 31 Aug 2009 17:18:47 GMT

SCLN is just as boring and frustrating as CHINA was, but unlike china, this one is holding above technical support at $4.50 (CHINA never really broke through support at $2.70 in any convincing fashion)…this makes SCLN a potential buy, but volume needs to get up to try to break the previous high of $4.84, or else there’s risk of a double top here in the mid $4s.[More...]

YM BioSciences (AMEX:YMI): Trading Below Cash With Multiple Catalysts

Mon, 10 Aug 2009 17:08:11 GMT

YM BioSciences (AMEX:YMI) (TSE:YM) (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on a fully diluted basis, which equates to a market cap of about US$34M and US$38M, respectively. Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting monoclonal antibody or MAb) is curr (...)[More...]

YM BioSciences Announces Phase 2 Metastatic Colorectal Cancer Results for Nimotuzumab

Tue, 05 Aug 2008 17:02:00 GMT

The table below compares nimotuzumab (nimo) + irinotecan (N-Mab + Iri) data against results obtained from an integrated analysis of four trials of patients treated with Erbitux (cetuximab) + irinotecan (C-Mab + Iri) following irinotecan failure in a similar patient population: YM BioSciences (YMI) announced preliminary results from a Phase 2 study of nimo in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The prospective primary endpoint in the trial is[More...]

NASDAQ Technical Picture - Overbought

Wed, 05 Sep 2007 13:31:32 GMT

Obtaining this clearance will be a transformative event for nimotuzumab and highlights the significant efforts made by YM staff in fiscal 2009 to advance our lead drug in an aligned effort with our licensees," said David Allan, Chairman and CEO of YM BioSciences.

[More...]

Ym Biosciences Reports Third Quarter 2009 Operational and Financial Results

Thu, 14 May 2009 11:52:00 GMT

MISSISSAUGA, ON, May 14 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the third quarter of fiscal 2009, ended March 31, 2009.
"Just a few days ago we reported critically important data at the 100th AACR conference in Denver highlighting the mechanistic differences between nimotuzumab and the EGFR targeting antibody, Erbitux(R)," said David Allan, Chairman and CEO of YM BioSciences.
With Erbitux(R) as the leading EGFR-targeting drug on the market and generating more than $1.5 billion in annual sales, these findings are profound and further define the significant opportunity for our lead product."

[More...]

YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB

Mon, 10 Aug 2009 10:55:00 GMT

MISSISSAUGA, ON, Aug. 10 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.[More...]

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

Mon, 29 Jun 2009 10:55:00 GMT

MISSISSAUGA, ON, June 29 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that YM's subsidiary, CIMYM BioSciences Inc. and Oncoscience AG have resolved the issues between the companies in a cooperative effort. CIMYM BioSciences has formally notified Oncoscience that it no longer intends to submit its application to the London Court of International Arbitration for resolution of the matters previously in dispute.[More...]

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

Tue, 23 Jun 2009 15:44:00 GMT

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. , a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its licensee for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan advises that it has commenced enrollment of a Phase II trial evaluating nimotuzumab in combination with radiation therapy/cisplatin/vinorelbine in first-line curative intent patients with Stage III non-small-cell lung cancer . The trial will evaluate the treatment completion rate and numerous secondary endpoints including response rate, progression-free survival, and the overall survival rate at 12 and 18 months as well as toxicity.[More...]

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

Mon, 01 Jun 2009 12:05:00 GMT

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting -[More...]

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

Mon, 01 Jun 2009 12:04:00 GMT

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al (Kidwai Memorial Institute of Oncology, Bangalore, India), were presented in a poster at the 2009 ASCO Annual Meeting. The trial demonstrates ...[More...]

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

Thu, 28 May 2009 21:40:00 GMT

MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomized trial of nimotuzumab in patients with head and neck cancer conducted by Biocon Limited , a licensee of CIMAB SA, YM's licensor, at the 45th Annual Meeting of the American Society of Clinical Oncology held in Orlando, Florida from May 29 to June 2, 2009.[More...]

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

Thu, 14 May 2009 10:55:00 GMT

MISSISSAUGA, ON, May 14 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the third quarter of fiscal 2009, ended March 31, 2009.[More...]